Merck KGaA

MKKGY · OTC

Share price · MKKGY

$31.67+4.03 (+14.58%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MKKGY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 25 Jun 2026+5.3%
  2. 13 May 2026+6.8%
  3. 5 Mar 2026-8.0%
  4. 13 Nov 2025+4.8%
  5. 16 Oct 2025-5.0%
  6. 2 Oct 2025-2.7%
  7. 1 Oct 2025+9.0%

Share of unusual movement by asset

For each asset, the share of MKKGY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lurbinectedin
events and moves
93%
Nirogacestat
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—97%

Assets

(8 total)
8Total Assets
7Approved
1Phase 3 / Filed
0Phase 1–2 / Early
10Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Approved
PD-L1Monoclonal antibody
Merkel Cell CarcinomaBladder / Urothelial CancerRenal Cell Carcinoma
Urothelial Carcinoma
Approved
EGFRMonoclonal antibody
Head and Neck Squamous Cell CarcinomaColorectal Cancer
Metastatic Colorectal Cancer
Approved
Adenosine deaminase-resistant purine analog · DNA synthesis machinery in lymphocytesSmall molecule
Multiple Sclerosis
Approved
Alkylating DrugSmall molecule
Small Cell Lung Cancer
Approved
Gamma-secretase (presenilin complex)Small molecule
Multiple MyelomaSoft Tissue Sarcoma
Desmoid Tumors
Approved
Interferon beta receptor (type I IFN signaling) · Type I interferon receptorBiologic (subtype unspecified)
Multiple Sclerosis
Tepotinib(Tepmetko)
Approved
METSmall molecule
Non-Small Cell Lung Cancer
Phase 3
CEACAM5Antibody–drug conjugate
Non-Small Cell Lung CancerColorectal Cancer
Metastatic Colorectal Cancer

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
CetuximabPhase 1/2Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms …
Est. primary completion 2027-04 · NCT04956640 · CT.gov ↗
What to watch
May 2027 (1)
NirogacestatPhase 2Desmoid Tumor, Aggressive Fibromatosis
Est. primary completion 2027-05-28 · NCT07170644 · CT.gov ↗
What to watch
December 2027 (1)
LurbinectedinPhase 3Relapsed Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT06496048 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
LurbinectedinPhase 1/2Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Est. primary completion 2028-01-28 · NCT05734066 · CT.gov ↗
What to watch
November 2028 (1)
CetuximabPhase 2Colorectal Neoplasms
Est. primary completion 2028-11 · NCT07814417 · CT.gov ↗
What to watch
2029 (2)
August 2029 (2)
LurbinectedinPhase 2Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-08-04 · NCT07459634 · CT.gov ↗
What to watch
LurbinectedinPhase 3Leiomyosarcoma
Est. primary completion 2029-08-30 · NCT06088290 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026WithdrawalLurbinectedin (Zepzelca)FDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication
US, FDA · Jazz Pharmaceuticals Ireland, Ltd. · Source ↗
June 2026Topline resultLurbinectedinPhase 3 LAGOON did not meet its overall survival primary endpoint
May 2026ApprovalCladribine (MAVENCLAD®)FDA updates Boxed Warning on Mavenclad (NDA022561)
US, FDA · FDA · Source ↗
7 October 2025FDA action dateLurbinectedinPDUFA date set for Zepzelca plus atezolizumab
US, FDA · Source ↗
2 October 2025ApprovalLurbinectedinFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
10 June 2025Filing acceptedLurbinectedinFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewLurbinectedinFDA grants Priority Review to Zepzelca plus atezolizumab sNDA
US, FDA · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$5.5B———report ↗

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 9 reporting institutions held 0.1M shares ($1.9M).

#InstitutionSharesValue
1Henry James International Management Inc.52,591$1.3M
2RHUMBLINE ADVISERS10,946$276K
3YOUSIF CAPITAL MANAGEMENT, LLC8,952$222K
4GAMMA Investing LLC1,701$43K
5PNC FINANCIAL SERVICES GROUP, INC.190$5K
6Salomon & Ludwin, LLC166$4K
7NBC SECURITIES, INC.162$4K
8Strive Financial Group ,LLC72$2K
9Hanson & Doremus Investment Management5$0